31. May 2019.
Hemofarm Marks 59 Years of Successful Operation

RECORD-BREAKING PRODUCTION ACCOMPANIED BY RECORD-BREAKING SALES

The leader in the pharmaceutical market of Serbia and the region and one of the largest exporters in Serbia, Hemofarm marked 59 years of successful operations. Hemofarm finished the previous year with a record-breaking output of 5.6 billion tablets when it also achieved record-breaking sales, it was pointed out at the traditional reception for employees, jubilarians, and pensioners in Vršac-based factory.

Hemofarm's success in Serbia is accompanied by results of factories in Bosnia and Herzegovina and Montenegro: Banja Luka-based Hemofarm is still a leader in B&H with a sales growth of 18%, while Podgorica-based Hemofarm achieved record-breaking production output in the past year. There were 318 people employed with Hemofarm Group in the last 12 months, i.e. between the two Company anniversaries.

State-of-the-art Hemofarm plants are in compliance with the highest international pharmaceutical standards and, with the high professionalism of staff, this company has become a guarantor of medicinal product quality for numerous European countries. As a result, over the past 10 years, production of more than 230 medicinal products has been transferred from European Union factories to Hemofarm production plants. According to the CEO of Hemofarm, Dr. Ronald Seeliger, it is precisely such company's willingness to adapt to the global market requirements, which is one of the main reasons for its success.

’Hemofarm, for example, has been prepared to implement the EU Falsified Medicines Directive (FMD) even before the deadline, which has been mandatory for all entities in the pharmaceutical supply chain as of February 9th this year. Without full implementation of this directive, we would not be able to export medicinal products to the European Union market, and Hemofarm has been delivering medicines in accordance with the new EU regulations, prior to the set deadline, i.e. since the beginning of the year’, - Dr. Seeliger pointed out on the occasion of Company Day.

According to him, every result is important for Hemofarm. ’Production and sales volume is the main indicator of success of each company, and we are proud of each individual result: the success that our medicinal product or preparation achieves in the market, the digitization process in our laboratories, the fact that many students have been employed in Hemofarm upon completion of studies. Each of these factors participates in the construction of company’s overall success’.

A great jubilee ahead of us

’We've gone a long way since the first product came out of our production lines 59 years ago. Now we are entering the great jubilee - the 60th year of operations. We have prepared many novelties for the upcoming period, with a clear intention to celebrate the past, and to look forward to the future’, Dr. Ronald Seeliger, Hemofarm’s CEO, said.

15. May 2019.
STADA Health Report 2019.
27. March 2019.
Delegation of the German Eastern Business Association Visits Hemomont
01. March 2019.
We Celebrated the 25th Anniversary of the Antibiotics Plant in Dubovac
Hemofarm A.D.
Beogradski put bb, 26300 Vršac, Serbia
tel +381 13 803 100, fax +381 13 803 100
Follow us: